Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT01608152
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 15 Years - 39 Years
- Healthy Volunteers
- Not accepted
Interventions
- Focus Group — BEHAVIORALAttend a focus group
- Internet-Based Intervention — OTHERHave access to the game
- Interview — BEHAVIORAL1 week after the 3-week period ends, interview conducted over the phone or at a clinic visit.
Study Details
This trial collects feedback from patients to develop a video game in improving the outcomes in stem cell transplant survivors. A video game may help to improve health behaviors for leukemia or lymphoma patients after stem cell transplant.
Key Dates
- Start date
- Feb 20, 2013
- Status verified
- Oct 2025
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 40 participants (estimated)
Arms
- Arm: Group I (focus group)Patients attend a focus group for up to 1.5 hours and provide feedback on design elements, specific desirable features, and preferences for the initial prototype.
- Arm: Group II (access to the game)Patients have access to the game for 3 weeks and then provide feedback on problems or questions regarding the use of the prototype.
Primary Outcome Measure
Feasibility of electronic game intervention [ Time Frame: 4 weeks ]
Central Contacts
- Susan Peterson, MPH,PhD713-792-8267
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | Susan K. Peterson 713-792-8267 Susan K. Peterson (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
By condition
By specialty
By research site
Related Studies
- Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)PHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALEPHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama